Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13365609 | 0.86 | ABL1 (0.42) | — | |
| SCHEMBL20232221 | 0.85 | HTR2A (0.44) | HTR2ACYP1A2CYP2A6ADRA1ATAAR1 | |
| SCHEMBL21565264 | 0.85 | NQO1 (0.48) | GAAHSD17B10CYP1A2 | |
| SCHEMBL18122879 | 0.85 | CYP2D6 (0.43) | HTR2ACYP1A2CYP2A6ADRA1A | |
| SCHEMBL27011337 | 0.83 | BRD4 (0.45) | HSD17B10 | |
| SCHEMBL14328441 | 0.83 | ABCB11 (0.45) | HTR2AHSD17B10ADRA1A | |
| SCHEMBL18926863 | 0.83 | HTR2A (0.49) | HTR2AGAAADRA1ATAAR1IDO1 | |
| SCHEMBL17471247 | 0.83 | GAA (0.53) | HTR2AGAACYP1A2CYP2A6ADRA1A | |
| SCHEMBL25564551 | 0.81 | KDM4E (0.43) | GAACYP1A2 | |
| SCHEMBL24345325 | 0.80 | NOS3 (0.44) | HTR2AGAACYP1A2CYP2A6ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159513-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159513-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, IL1B, IL1RN | HTR2A 2617/4885GAA 288/4885HSD17B10 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.